Luye Pharma Group Ltd (2186)

Currency in HKD
2.94
-0.03(-1.01%)
Closed·
2186 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.912.98
52 wk Range
1.674.49
Key Statistics
Bid/Ask
2.94 / 2.94
Prev. Close
2.97
Open
2.97
Day's Range
2.91-2.98
52 wk Range
1.67-4.49
Volume
6.83M
Average Volume (3m)
20.63M
1-Year Change
46.27%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2186 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.61
Upside
+22.80%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low Price / Book multiple

Luye Pharma Group Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Luye Pharma Group Ltd Company Profile

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; research and development of antibody drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People’s Republic of China.

Employees
5115
Market
Hong Kong

Compare 2186 to Peers and Sector

Metrics to compare
2186
Peers
Sector
Relationship
P/E Ratio
26.4x20.7x−0.6x
PEG Ratio
−0.550.310.00
Price/Book
0.7x3.0x2.6x
Price / LTM Sales
1.7x3.6x3.4x
Upside (Analyst Target)
26.6%10.5%41.1%
Fair Value Upside
Unlock2.9%5.3%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.61
(+22.80% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Buy5.00+70.07%3.10MaintainSep 02, 2025
Goldman Sachs
Hold3.70+25.85%3.25MaintainSep 01, 2025
Goldman Sachs
Hold3.25+10.54%2.42MaintainJul 09, 2025
Goldman Sachs
Hold2.42-17.69%2.79MaintainApr 17, 2025
Citi
Buy3.10+5.44%4.00MaintainApr 03, 2025

Earnings

Latest Release
Sep 29, 2025
EPS / Forecast
0.08 / --
Revenue / Forecast
3.18B / --
EPS Revisions
Last 90 days

2186 Income Statement

People Also Watch

35.82
2367
-0.61%
29.20
0148
+1.11%
21.46
0683
+1.80%

FAQ

What Is the Luye Pharma Group (2186) Stock Price Today?

The Luye Pharma Group stock price today is 2.94

What Stock Exchange Does Luye Pharma Group Trade On?

Luye Pharma Group is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Luye Pharma Group?

The stock symbol for Luye Pharma Group is "2186."

What Is the Luye Pharma Group Market Cap?

As of today, Luye Pharma Group market cap is 11.74B.

What Is Luye Pharma Group's Earnings Per Share (TTM)?

The Luye Pharma Group EPS (TTM) is 0.11.

From a Technical Analysis Perspective, Is 2186 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Luye Pharma Group Stock Split?

Luye Pharma Group has split 0 times.

How Many Employees Does Luye Pharma Group Have?

Luye Pharma Group has 5115 employees.

What is the current trading status of Luye Pharma Group (2186)?

As of Jan 18, 2026, Luye Pharma Group (2186) is trading at a price of 2.94, with a previous close of 2.97. The stock has fluctuated within a day range of 2.91 to 2.98, while its 52-week range spans from 1.67 to 4.49.

What Is Luye Pharma Group (2186) Price Target According to Analysts?

The average 12-month price target for Luye Pharma Group is HKD3.61039266, with a high estimate of HKD5.02852668 and a low estimate of HKD2.08188835. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +22.80% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.